TQB2102 for HER2-mutated non-small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, TQB2102, for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene and has stopped responding to standard treatments. It aims to see if the drug can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that cannot be removed by surgery or cured with radiation and chemotherapy together.
- You are between 18 and 75 years old.
- You have already tried standard treatments, and they are no longer working.
- You have at least one tumor that can be measured on scans.
- You have a HER2 gene abnormality in your cancer cells (the doctor will check this).
- You agree to use contraception if there is any chance of pregnancy, and you are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new targeted drug, TQB2102, for women with advanced or recurrent gynecologic cancers that have some HER2 protein. It may be an option if your cancer has continued to grow after platinum chemotherapy.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.